Erythema Nodosum–like Eruption in the Setting of Sorafenib Therapy

Treatment with sorafenib, a small-molecule multikinase inhibitor (MKI) of the serine-threonine kinases CRAF and BRAF; vascular endothelial growth factor receptors 1, 2, and 3; and platelet-derived growth factor receptor β, may result in numerous cutaneous toxic effects, including hyperkeratotic hand-foot skin reaction, maculopapular or papulopustular eruptions, erythema multiforme, generalized keratosis pilaris–like eruption, and alopecia.¹ Here we report the first case to our knowledge of erythema nodosum (EN)-like eruption concurrent with sorafenib therapy.